-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ocedurenone in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dotinurad in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dotinurad in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dotinurad in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lorundrostat Hydrobromide in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lorundrostat Hydrobromide in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lorundrostat Hydrobromide in Chronic Kidney Disease (Chronic...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ravulizumab LA in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Chronic Kidney Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BAY-3283142 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BAY-3283142 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BAY-3283142 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BI-685509 in Chronic Kidney Disease (Chronic Renal Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BI-685509 in Chronic Kidney Disease (Chronic Renal Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BI-685509 in Chronic Kidney Disease (Chronic Renal Failure)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DISC-0974 in Anemia in Chronic Kidney Disease (Renal Anemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DISC-0974 in Anemia in Chronic Kidney Disease (Renal Anemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DISC-0974 in Anemia in Chronic Kidney Disease...
-
Product Insights
NewChronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024
Empower your strategies with our Chronic Kidney Disease (Chronic Renal Failure) – Drugs In Development, 2024 report and make more profitable business decisions. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups, and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity, and high cholesterol. The Chronic Kidney Disease (Chronic Renal...
-
Product Insights
NewHyperphosphatemia In Chronic Kidney Disease – Drugs In Development, 2024
Empower your strategies with our Hyperphosphatemia In Chronic Kidney Disease – Drugs In Development, 2024 report and make more profitable business decisions. Hyperphosphatemia, abnormally high serum phosphate levels, can result from increased phosphate intake, decreased phosphate excretion, or a disorder that shifts intracellular phosphate to extracellular space. This condition is most commonly seen in patients with chronic kidney disease (CKD). Signs and symptoms include fatigue, nausea, sleep disturbances, shortness of breath, bone and joint pain, pruritus, and rash. Treatment includes phosphate...
-
Product Insights
NewAnemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2024
Empower your strategies with our Anemia in Chronic Kidney Disease (Renal Anemia) – Drugs In Development, 2024 report and make more profitable business decisions. Renal anemia is a disease in which the patient has an unusually low count of red blood cells associated with kidney disease. This type of anemia is caused by a lack of erythropoietin, a protein produced in the kidneys that helps to create red blood cells. Symptoms caused by renal anemia include pale skin and gums, shortness...